Pharmaron Beijing : PROPOSED REDUCTION OF REGISTERED CAPITAL AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
March 28, 2021 at 06:22 am EDT
Share
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
Pharmaron Beijing Co., Ltd.*
ੰᎲʷϓ€̏ԯอᖹҦஔٰ΅Ϟࠢʮ̡
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 3759)
PROPOSED REDUCTION OF REGISTERED CAPITAL
AND
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
The Board of directors (the "Board") of Pharmaron Beijing Co., Ltd.* (the "Company") has proposed at the meeting of the Board held on Friday, March 26, 2020 to seek the approval of the shareholders of the Company at the annual general meeting to be convened to approve, among others, (1) the repurchase and cancellation of 193,024 restricted A shares granted under the A share incentive scheme adopted by the Company on August 15, 2019 (the "A Share Incentive Scheme") due to the resignation of the three grantees of such restricted A shares (the "Proposed Repurchase and Cancellation") in accordance with the provisions of the A Share Incentive Scheme; (2) the reduction of registered capital from RMB794,387,462 to RMB794,194,438 and the decrease of number of issued shares of the Company from 794,387,462 shares to 794,194,438 shares, upon approval by the shareholders and completion of the Proposed Repurchase and Cancellation (the "Proposed Reduction of Registered Capital"); and (3) the following proposed amendments (the "Proposed Amendments") to the Articles of Association of the Company (the "Articles") in light of the Proposed Repurchase and Cancellation and the Proposed Reduction of Registered Capital:
Table of comparison of the Proposed Amendment to the Articles
Before amendment
After amendment
Article 6 The registered capital of the Company is RMB794,387,462.
Article 6 The registered capital of the Company is RMB794,194,438.
Article 21 The shareholding structure of the Company is: 794,387,462 ordinary shares, including 660,370,962 shares held by holders of domestic-listed domestic shares, and 134,016,500 shares held by holders of H shares.
Article 21 The shareholding structure of the Company is: 794,194,438 ordinary shares, including 660,177,938 shares held by holders of domestic-listed domestic shares, and 134,016,500 shares held by holders of H shares.
GENERAL INFORMATION
A circular containing, among other things, details about the Proposed Repurchase and Cancellation, the Proposed Reduction of Registered Capital and the Proposed Amendments will be despatched to the shareholders of the Company as soon as practicable.
By order of the Board
Pharmaron Beijing Co., Ltd.*
ੰᎲʷϓ€̏ԯอᖹҦஔٰ΅Ϟࠢʮ̡
Dr. Lou Boliang
Chairman
Beijing, the PRC
March 28, 2021
As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Chen Pingjin, Mr. Hu Baifeng, Mr. Li Jiaqing and Mr. Zhou Hongbin as non-executive Directors; Mr. Dai Lixin, Ms. Chen Guoqin, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.
*For identification purposes only
Attachments
Original document
Permalink
Disclaimer
Pharmaron Beijing Co. Ltd. published this content on 28 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 March 2021 10:21:00 UTC.
Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows:
- laboratory services (61.3%);
- development and production of chemical processes and formulations (23.5%);
- clinical research services (12.8%);
- other (2.4%);
Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).